LHDX News and Press, Lucira Health Inc. From 08/02/22

EMERYVILLE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced t...

Gainers: Canoo ( GOEV ) +28% . Kaspien Holdings ( KSPN ) +18% . Clever Leaves Holdings ( CLVR ) +20% . Yatsen Holding ( YSG ) +17% . Lucira Health ( LHDX ) +17% . Revelation Biosciences ( REVB ) +16% . Kopin Corpo...

Gainers: Data Storage Corporation (DTST) +40%. Indonesia Energy Corporation (INDO) +30%. Harpoon Therapeutics (HARP) +28%. Pulse Biosciences (PLSE) +24%. Praxis Precision Medicines (PRAX) +24%. Xeris Biopharma Holdings (XERS) +24%. Griffon Corporation (GFF) +22%. New Concept Energy (GBR) +20%...

Lucira Health, Inc. (LHDX) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Louisa Smith - Gilmartin Group, IR Erik Engelson - President, CEO Dan George - CFO Conference Call Participants Brian Weinstein - William Blair Rahul Rakhit - LifeSci Capital Presentation ...

Image source: The Motley Fool. Lucira Health, Inc. (NASDAQ: LHDX) Q1 2022 Earnings Call May 12, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Lucira Health, Inc. (LHDX) Q1 2022 Earnings Call Transcript

Lucira Health press release (NASDAQ:LHDX): Q1 GAAP EPS of $0.31 beats by $0.22. Revenue of $90.5M (vs. $4.5M last year) beats by $4.15M. Revenue growth was driven by COVID-19 test sales. Withdrawing previously announced 2022 annual revenue guidance of $450.0 million, due to the unpredictable ...

EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology company focused on the development and commercialization of transformative and innovative infe...

Lucira Health (NASDAQ:LHDX) said it submitted a request to the U.S. Food and Drug Administration for emergency use authorization (EUA) of its COVID-19 & Flu test. The company said the request is for prescription at-home use of the PCR-quality test for COVID-19 or Influenza. Lucira is seek...

EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of innovative infectious disease tests, announced today that it has submitted a request to the...

Lucira Health (NASDAQ:LHDX) on Monday said both its COVID-19 & flu and COVID-19 molecular tests have been cleared for sale and distribution throughout the European Union. Both tests developed by the company run on a palm-sized device with no separate instrument or reader and produce resul...